Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer

Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer

NCT01956812 ·Status: TERMINATED ·Phase: PHASE3

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

NCT07214298 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy

NCT03956056 ·Status: TERMINATED ·Phase: PHASE1

Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

NCT05034627 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Gene Expression Profiles in Patients With Metastatic Pancreatic Cancer

NCT00897741 ·Status: COMPLETED

Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)

NCT05642962 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer

NCT02570711 ·Status: TERMINATED ·Phase: PHASE2

A Safety Study Using Pentamidine in Patients With Pancreatic Cancer Undergoing Standard Therapy

NCT00810953 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer

NCT00003677 ·Status: COMPLETED ·Phase: PHASE2

Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC

NCT03634332 ·Status: UNKNOWN ·Phase: PHASE2

A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer

NCT01181245 ·Status: COMPLETED ·Phase: PHASE1

Dasatinib in Treating Patients With Stage IV Pancreatic Cancer

NCT00544908 ·Status: TERMINATED ·Phase: PHASE2

Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer

NCT07262567 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy

NCT05927142 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma

NCT03979066 ·Status: TERMINATED ·Phase: PHASE2

Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

NCT05913661 ·Status: UNKNOWN ·Phase: PHASE2

Nimotuzumab in Adults With Pancreatic Cancer

NCT00561990 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Dasatinib in Treating Patients With Metastatic Pancreatic Cancer

NCT00474812 ·Status: COMPLETED ·Phase: PHASE2

Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2)

NCT00655785 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI

NCT03693677 ·Status: COMPLETED ·Phase: PHASE2

Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery

NCT04161755 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Efficacy of PERT for PEI in Unresectable Pancreatic Cancer.

NCT06099119 ·Status: RECRUITING ·Phase: PHASE4

Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

NCT05093231 ·Status: RECRUITING ·Phase: PHASE2

Gemcitabine and Monoclonal Antibody Therapy in Treating Patients With Metastatic Cancer of the Pancreas

NCT00003797 ·Status: UNKNOWN ·Phase: PHASE2

Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

NCT01660971 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1